Inversago Pharma specializes in the development of new therapies focusing on CB1
blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists.
- Year invested 2022
- Investment Stage Early
- Board Members
- Sectors
- Investment Status Current
- Associated Team
- Website inversago.com
- Company Status Private